By Dr. Priyom Bose, Ph.D. Reviewed by Lauren Hardaker Apr 21 2026 Despite successfully removing amyloid plaques from the brain, widely anticipated antibody therapies fail to deliver meaningful cognitive improvements, raising critical questions about the future direction of Alzheimer’s treatment. Study: Amyloid‐beta‐targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Image credit: Kateryna Kon/Shutterstock.com Scientists have